Ovid Therapeutics Board Member Grants $45K RSU—Insider Confidence Signals Boost Amid KCC2 Buzz
Ovid Therapeutics’ latest RSU grant for board member Stelios Papadopoulos signals insider confidence, boosting investor optimism ahead of the KCC2 data release.
3 minutes to read